Search clinical trials for: EV/DNG (Qlaira, BAY86-5027)

Total 59 results

Bayer

Completed

Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea

Contraception

Korea, Republic of
Bayer

Completed

Study to Investigate Efficacy and Safety of a New Oral Contraceptive

Contraception

Germany, Austria, Spain
Bayer

Completed

Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy

Contraception

Mexico
Bayer

Completed

Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects

Contraception

China, Taiwan, Thailand, India, Hong Kong
Bayer

Completed

Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens

Ovulation Inhibition

Germany, Netherlands
Bayer

Completed

Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding

Metrorrhagia

China, Taiwan, Singapore, Philippines, Russian Federation, Thailand
Bayer

Completed

Efficacy and Safety Study of an Oral Contraceptive in Healthy Females

Contraception

United States, Canada
Bayer

Completed

Impact of SH T00658ID as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D01155E) on Hemostatic Parameters

Pregnancy, Unplanned

Netherlands
Bayer

Completed

Comparative Cycle Control Europe

Contraception

Germany, Czech Republic, France
Bayer

Completed

Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction

Contraceptives, Oral

Slovakia, France, Germany, Hungary, Sweden, Czech Republic, Italy, Russian Federation, United Kingdom, Greece, Israel
Bayer

Completed

Wellnara Post-marketing Surveillance in Japan (WELLNARA)

Osteoporosis, Postmenopausal

Japan
Bayer

Completed

Effects of SH T00658ID on Libido

Contraception | Libido

Belgium, Australia, Germany, Thailand, Spain, Austria, Italy
Bayer

Completed

Metabolism Study to Investigate the Impact of a Sequential Oral Contraceptive

Contraception

Germany
Bayer

Completed

Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache

Headache | Pelvic Pain | Oral Contraceptive

Finland, France, Switzerland, Australia, Germany, Thailand, Mexico, United Kingdom, Spain
Bayer

Completed

Effects of Wellnara on Climacteric Symptoms

Postmenopause

Germany
Bayer

Completed

Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain

Endometriosis

Spain, Sweden, France, Finland, Denmark, Netherlands, Czech Republic
Bayer

Completed

Fat Distribution in Healthy Early Postmenopausal Women

Healthy | Postmenopause

Austria
Bayer

Completed

Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)

Contraception

Sweden, Finland, Hungary, Norway, United Kingdom
Bayer

Completed

Bioequivalence Study: 2 mg Estradiol Valerate (EV) and 3 mg Dienogest (DNG) Without and With Levomefolate Calcium

Pharmacology, Clinical

Germany
Bayer

Completed

A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components (INDessa)

Contraception

Germany, United Kingdom
Bayer

Completed

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Metrorrhagia

Sweden, Germany, Poland, Finland, Australia, Czech Republic, Hungary, Netherlands, Ukraine, United Kingdom
Bayer

Completed

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

Metrorrhagia

United States, Canada
Bayer

Completed

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

Contraception

Belgium, United States, Russian Federation, Germany, Austria
Bayer

Completed

Bioequivalence Study: 3 mg Estradiol Valerate (EV) With and Without Levomefolate Calcium

Contraception | Ovulation Inhibition

Germany
Bayer

Completed

Scandinavian Mirena Insertion Nulliparous Trial.

Nulliparous

Sweden
Bayer

Completed

Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding

Menorrhagia

Italy
Bayer

Completed

LCS12 Adolescent Study

Contraception

Belgium, Sweden, Austria, Finland, Netherlands, Germany, Denmark, Norway
Bayer

Completed

Mirena Efficiency and Tolerability During the First Year of Use

Contraception | Medicated Intrauterine Devices

France
Bayer

Completed

A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years (ANALIA)

Intrauterine Devices, Medicated

Spain
Bayer

Completed

Mirena in Idiopathic Menorrhagia

Idiopathic Menorrhagia

Croatia, Saudi Arabia, Bulgaria, Jordan, Romania, Russian Federation, Turkey, United Arab Emirates, Kuwait, India, Pakistan, Serbia, Sri Lanka
Bayer

Completed

Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea (J-MIRAI)

Menorrhagia, Dysmenorrhea

Japan
Bayer

Completed

GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

Contraception

China, Korea, Republic of, Australia
Bayer

Completed

Mirena Extension Trial (MET)

Contraception

United States
Bayer

Completed

An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method (JULIA)

Quality of Life

Spain
Bayer

Completed

Mirena Observational Program

Endometrial Hyperplasia | Contraception | Menorrhagia | Estrogen Replacement Therapy

Kazakhstan
Bayer
Karolinska Institutet, Stockholm, Sweden

Active, not recruiting

JAYDESS Drug Utilization Study in Sweden

Contraception

Sweden
Bayer

Completed

Mirena Post-marketing Surveillance in Japan

Contraception

Japan
Bayer

Completed

Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice (MARILIA)

Female Contraception

Algeria
Bayer

Completed

Effect on Primary Dysmenorrhea

Primary Dysmenorrhea

Italy, Chile, United States, Philippines, Canada, Germany
Bayer

Completed

Cross -Over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel (LEVEQ-2)

Contraception | Contraception, Postcoital

Mexico
Bayer

Completed

Acceptability of Long-term Progestin-only Contraception in Europe

Contraception

Slovakia, France, United Kingdom, Ireland
Bayer

Completed

Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel (LEVEQ-1)

Contraception | Contraception, Postcoital

Mexico
Bayer
University of Utah

Completed

Duration of Use of Highly Effective Reversible Contraception

Pregnancy

United States
Bayer

Completed

Non-interventional Study of Long-term Intrauterine Contraceptives Acceptability and User Satisfaction (Mirabel)

Contraception

Russian Federation
Bayer

Completed

To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)

Contraception

United States, Canada
Bayer

Completed

Cross-over Study to Prove Bioequivalence Between Two Oral Formulations of Levonorgestrel 1.5 mg (LEVEQ-3)

Contraceptives, Postcoital

Mexico
Bayer

Completed

Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis

Osteoporosis | Hypogonadism | Paraplegia | Bone Density

Germany
Bayer

Completed

Mirena or Conventional Medical Treatment for Menorrhagia

Menorrhagia

China, Indonesia, Korea, Republic of, Malaysia, Thailand, Taiwan, Hong Kong, Pakistan
Bayer

Terminated

NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH)

Hypogonadism

Germany
Bayer

Completed

Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice (IPASS Nebido)

Hypogonadism | Male

Germany, Indonesia, Korea, Republic of, Malaysia, Saudi Arabia, Singapore, Spain, Thailand, Philippines, Taiwan, Australia, Austria, Bulgaria, Colombia, Czech Republic, Estonia, Hong Kong, Italy, Jordan, Kazakhstan, Latvia, Lebanon, Lithuani... and more

3

Subscribe